Renaissance Technologies LLC Increases Stake in Kura Oncology, Inc. (NASDAQ:KURA)

Renaissance Technologies LLC lifted its position in Kura Oncology, Inc. (NASDAQ:KURA) by 463.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 597,810 shares of the company’s stock after acquiring an additional 491,700 shares during the quarter. Renaissance Technologies LLC’s holdings in Kura Oncology were worth $5,207,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in KURA. Harbor Advisors LLC bought a new stake in Kura Oncology in the fourth quarter worth about $87,000. E Fund Management Co. Ltd. purchased a new stake in shares of Kura Oncology in the fourth quarter worth approximately $90,000. Corient Private Wealth LLC bought a new stake in shares of Kura Oncology during the 4th quarter worth approximately $109,000. Teacher Retirement System of Texas boosted its holdings in Kura Oncology by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company’s stock valued at $120,000 after acquiring an additional 2,285 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new stake in Kura Oncology in the fourth quarter worth $127,000.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Kura Oncology in a research note on Tuesday, April 8th. UBS Group reduced their target price on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. Cantor Fitzgerald raised Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. Scotiabank decreased their target price on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.50.

Kura Oncology Stock Performance

Shares of Kura Oncology stock opened at $5.90 on Monday. Kura Oncology, Inc. has a one year low of $5.41 and a one year high of $23.48. The company has a market capitalization of $476.59 million, a PE ratio of -2.50 and a beta of 0.83. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The company has a 50-day simple moving average of $7.07 and a two-hundred day simple moving average of $10.34.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analysts’ expectations of $57.96 million. Research analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock valued at $92,307 in the last quarter. 5.50% of the stock is currently owned by corporate insiders.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.